Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityNo recent work listed

Qian Zhan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3266-806X; OpenAlex author ID A5100664085. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 5 papers · 2022: 1 paper

Papers 20

  1. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study. Co-author DOI 10.1186/s12885-022-09719-6↗
  2. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. Co-author DOI 10.1016/j.ebiom.2021.103716↗
  3. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2021.01.010↗
  4. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s13045-021-01072-8↗
  5. A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.634881↗
  6. Construction and Validation of Novel Nomograms for Predicting Prognosis of Pancreatic Ductal Adenocarcinoma After Surgery According to Different Primary Cancer… Co-author DOI 10.3389/fonc.2021.646082↗
  7. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cam4.3425↗
  8. SHCBP1 interacting with EOGT enhanced O-GlcNAcylation of NOTCH1 and promoted the development of pancreatic cancer . Co-author DOI 10.21203/rs.3.rs-95104/v1↗
  9. Corrigendum to "GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer" [Cancer Le… Co-author DOI 10.1016/j.canlet.2019.03.031↗
  10. An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914557116↗
  11. MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway b… Co-author DOI 10.1002/jcb.26270↗
  12. lncRNA MEG3 had anti-cancer effects to suppress pancreatic cancer activity. Co-author DOI 10.1016/j.biopha.2017.02.041↗
  13. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic … Co-author DOI 10.1186/s12943-017-0738-0↗
  14. Effect of region of interest size on ADC measurements in pancreatic adenocarcinoma. Co-author DOI 10.1186/s40644-017-0116-6↗
  15. GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.06.016↗
  16. The Interplay Between miR-148a and DNMT1 Might be Exploited for Pancreatic Cancer Therapy. Co-author DOI 10.3109/07357907.2015.1025794↗
  17. Outcomes of robotic surgery for pancreatic ductal adenocarcinoma. Co-author DOI 10.3978/j.issn.1000-9604.2015.05.05↗
  18. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.2126↗
  19. Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Co-author DOI 10.1007/s00441-013-1711-x↗
  20. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-013-0903-z↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 17 shared papers, 2013–2022 · strength 1.36
  2. Chenghong Peng · 13 shared papers, 2013–2021 · strength 0.87
  3. Hao Chen · 11 shared papers, 2013–2022 · strength 0.83
  4. Xiaxing Deng · 8 shared papers, 2013–2022 · strength 0.67
  5. Shi Chen · 7 shared papers, 2014–2021 · strength 0.66
  6. Chenlei Wen · 6 shared papers, 2017–2022 · strength 0.59
  7. Cheng‐Yu Liao · 4 shared papers, 2020–2021 · strength 0.45
  8. Can Yang · 4 shared papers, 2020–2021 · strength 0.45
  9. Yifeng Tian · 4 shared papers, 2020–2021 · strength 0.45
  10. Xiongxiong Lu · 6 shared papers, 2013–2022 · strength 0.43
  11. Siyi Zou · 3 shared papers, 2021–2022 · strength 0.37
  12. Dongfeng Cheng · 4 shared papers, 2017–2021 · strength 0.33
  13. Zuwei Wang · 3 shared papers, 2020–2021 · strength 0.32
  14. Long Huang · 3 shared papers, 2020–2021 · strength 0.32
  15. Jiangning Gu · 4 shared papers, 2016–2020 · strength 0.30
  16. Jiabin Jin · 5 shared papers, 2013–2021 · strength 0.30
  17. Xiaxing Deng · 5 shared papers, 2013–2019 · strength 0.28
  18. Xinjing Wang · 3 shared papers, 2017–2022 · strength 0.28
  19. Yi Zhu · 4 shared papers, 2014–2019 · strength 0.26
  20. Yangbing Jin · 2 shared papers, 2021 · strength 0.22
  21. Jiancheng Wang · 2 shared papers, 2020–2021 · strength 0.18
  22. Jun Zhang · 2 shared papers, 2020–2021 · strength 0.18
  23. Yuan Fang · 4 shared papers, 2013–2019 · strength 0.18
  24. Yanling Chen · 2 shared papers, 2014–2021 · strength 0.16
  25. Jiewei Lin · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.